GSK
GSK
911 hedge funds and large institutions have $13.3B invested in GSK in 2024 Q1 according to their latest regulatory filings, with 99 funds opening new positions, 328 increasing their positions, 298 reducing their positions, and 77 closing their positions.
79% more call options, than puts
Call options by funds: $195M | Put options by funds: $109M
29% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 77
23% more capital invested
Capital invested by funds: $10.8B → $13.3B (+$2.52B)
10% more repeat investments, than reductions
Existing positions increased: 328 | Existing positions reduced: 298
8% more funds holding in top 10
Funds holding in top 10: 13 → 14 (+1)
2% more funds holding
Funds holding: 896 → 911 (+15)
0.43% more ownership
Funds ownership: 7.08% → 7.51% (+0.43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JEST
JTC Employer Solutions Trustee
St Helier,
Jersey
|
+$363M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$215M |
| 3 |
Morgan Stanley
New York
|
+$162M |
| 4 |
Citigroup
New York
|
+$81M |
| 5 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
+$62.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$112M |
| 2 |
Millennium Management
New York
|
-$59.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$55.8M |
| 4 |
MIS
Morningstar Investment Services
Chicago,
Illinois
|
-$52.6M |
| 5 |
AC
Armistice Capital
New York
|
-$50.8M |
GSK Hedge Fund Activity: Q1 2024 in Review
911 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2024, worth a combined $13.3B — up 23% from $10.8B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new GSK positions and 77 closed out — a net gain of 22 holders — while 328 added to existing stakes and 298 trimmed.
The largest buyer was JTC Employer Solutions Trustee, adding an estimated $363M. The largest seller was Arrowstreet Capital, cutting an estimated $112M.
- 911 institutional investors held GSK (GSK) as of Q1 2024, up from 896 in Q4 2023.
- Funds reported $13.3B of GSK stock for Q1 2024, up 23% quarter-over-quarter.
- 99 funds opened new GSK positions in Q1 2024 and 77 closed out, a net change of +22 holders.
- The largest GSK buyer in Q1 2024 was JTC Employer Solutions Trustee, an estimated $363M added.
- The largest GSK seller in Q1 2024 was Arrowstreet Capital, an estimated $112M sold.
Based on aggregated 13F filings for Q1 2024.